Prognostic Value of Complement System in NSCLC and its Association with PD-1 and PD-L1 Expression

被引：1

作者：

Ajona, D. ^{[1
]}

Pajares, M. J. ^{[2
]}

Freire, J. ^{[3
]}

Gomez-Roman, J. ^{[3
]}

Martinez-Terroba, E. ^{[4
]}

Ortiz-Espinosa, S. ^{[4
]}

Lledo, A. ^{[4
]}

Arenas-Lazaro, E. ^{[4
]}

Agorreta, J. ^{[4
]}

Lecanda, F. ^{[4
]}

Montuenga, L. ^{[4
]}

Pio, R. ^{[4
]}

机构：

[1] Cima Univ Navarra Idisna Ciberonc, Program Solid Tumors & Biomarkers, Pamplona, Spain

[2] Univ Navarra, Ctr Appl Med Res CIMA, Program Solid Tumors, Pamplona, Spain

[3] Univ Hosp Marques Valdecilla, Santander, Spain

[4] Cima, Pamplona, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

PD-L1; Prognosis; Complement system;

D O I：

10.1016/j.jtho.2018.08.407

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA11.06

引用

页码：S394 / S394

页数：1

共 50 条

[11] PD-1/PD-L1 as a prognostic factor in leukemia
Hadi Rezaeeyan
Seyedeh Nafiseh Hassani
Mojgan Barati
Mohammad Shahjahani
Najmaldin Saki
Journal of Hematopathology, 2017, 10 : 17 - 24
[12] Expression Pattern of Immune Checkpoints PD-1 and PD-L1 in Retinoblastoma and ITS Prognostic Significance
Singh, L.
Kashyap, S.
Sen, S.
Rizvi, M. A.
PEDIATRIC BLOOD & CANCER, 2017, 64 : S278 - S278
[13] PD-1/PD-L1 as a prognostic factor in leukemia
Rezaeeyan, Hadi
Hassani, Seyedeh Nafiseh
Barati, Mojgan
Shahjahani, Mohammad
Saki, Najmaldin
JOURNAL OF HEMATOPATHOLOGY, 2017, 10 (01) : 17 - 24
[14] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
Monneur, Audrey
Goncalves, Anthony
Bertucci, Francois
BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
[15] Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma
Owen, Dwight
Chu, Benjamin
Lehman, Amy M.
Annamalai, Lakshmanan
Yearley, Jennifer H.
Shilo, Konstantin
Otterson, Gregory A.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1204 - 1212
[16] Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
Lee, Lik Hang
Cavalcanti, Marcela S.
Sega, Neil H.
Hechtman, Jaclyn F.
Weiser, Martin R.
Smith, J. Joshua
Garcia-Aguilar, Julio
Sadot, Eran
Ntiamoah, Peter
Markowitz, Arnold J.
Shike, Moshe
Stadler, Zsofia K.
Vakiani, Efsevia
Klimstra, David S.
Shia, Jinru
MODERN PATHOLOGY, 2016, 29 (11) : 1433 - 1442
[17] PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
Schmidt, Lars Henning
Kuemmel, Andreas
Goerlich, Dennis
Mohr, Michael
Broeckling, Sebastian
Mikesch, Jan Henrik
Gruenewald, Inga
Marra, Alessandro
Schultheis, Anne M.
Wardelmann, Eva
Mueller-Tidow, Carsten
Spieker, Tilmann
Schliemann, Christoph
Berdel, Wolfgang E.
Wiewrodt, Rainer
Hartmann, Wolfgang
PLOS ONE, 2015, 10 (08):
[18] EVIDENCE-BASED VALUE OF PD-1 / PD-L1 INHIBITORS IN NSCLC: COMPARISON OF VALUE TO PRICE
Doyle, J. J.
Wood, B.
VALUE IN HEALTH, 2018, 21 : S91 - S91
[19] PD-L1 expression in NSCLC
Janzic, U.
Kern, I.
Janzic, A.
Cavka, L.
Cufer, T.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
[20] Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors
Sampedro-Nunez, Miguel
Serrano-Somavilla, Ana
Adrados, Magdalena
Cameselle-Teijeiro, Jose M.
Blanco-Carrera, Concepcion
Manuel Cabezas-Agricola, Jose
Martinez-Hernandez, Rebeca
Martin-Perez, Elena
Munoz de Nova, Jose Luis
Angel Diaz, Jose
Garcia-Centeno, Rogelio
Caneiro-Gomez, Javier
Abdulkader, Ihab
Gonzalez-Amaro, Roberto
Marazuela, Monica
SCIENTIFIC REPORTS, 2018, 8

← 1 2 3 4 5 →